E. Grigoryeva

771 total citations
5 papers, 393 citations indexed

About

E. Grigoryeva is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, E. Grigoryeva has authored 5 papers receiving a total of 393 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 2 papers in Immunology and 1 paper in Molecular Biology. Recurrent topics in E. Grigoryeva's work include Cancer Immunotherapy and Biomarkers (4 papers), CAR-T cell therapy research (3 papers) and Immunotherapy and Immune Responses (2 papers). E. Grigoryeva is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), CAR-T cell therapy research (3 papers) and Immunotherapy and Immune Responses (2 papers). E. Grigoryeva collaborates with scholars based in United States, Germany and Spain. E. Grigoryeva's co-authors include Dirk Schadendorf, Piotr Rutkowski, Paolo A. Ascierto, Inge Marie Svane, Abdel Saci, René González, Nicolás Meyer, Célèste Lebbé, Alexander M. Menzies and Thomas Eigentler and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Vrach.

In The Last Decade

E. Grigoryeva

5 papers receiving 386 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. Grigoryeva United States	4	364	129	97	71	21	5	393
Camille L. Gérard Switzerland	10	196 0.5×	80 0.6×	97 1.0×	85 1.2×	16 0.8×	33	300
Bożena Cybulska-Stopa Poland	11	246 0.7×	81 0.6×	102 1.1×	73 1.0×	5 0.2×	58	330
J.B.A.G. Haanen Netherlands	11	386 1.1×	165 1.3×	99 1.0×	60 0.8×	5 0.2×	33	468
J. Menezes United States	11	469 1.3×	165 1.3×	98 1.0×	227 3.2×	7 0.3×	24	544
Erika Castillo Gutiérrez Chile	7	237 0.7×	131 1.0×	66 0.7×	26 0.4×	7 0.3×	8	268
Annelieke E.C.A.B. Willemsen Netherlands	10	145 0.4×	40 0.3×	89 0.9×	102 1.4×	11 0.5×	25	298
Diego Enrico Argentina	8	136 0.4×	45 0.3×	42 0.4×	64 0.9×	6 0.3×	29	215
J.C. Hassel Germany	8	243 0.7×	86 0.7×	104 1.1×	31 0.4×	4 0.2×	16	278
Cor H. van der Leest Netherlands	7	206 0.6×	93 0.7×	44 0.5×	110 1.5×	2 0.1×	16	289
Amélie Boespflug France	9	241 0.7×	58 0.4×	84 0.9×	97 1.4×	2 0.1×	21	340

Countries citing papers authored by E. Grigoryeva

Since Specialization

Citations

This map shows the geographic impact of E. Grigoryeva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Grigoryeva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Grigoryeva more than expected).

Fields of papers citing papers by E. Grigoryeva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Grigoryeva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Grigoryeva. The network helps show where E. Grigoryeva may publish in the future.

Co-authorship network of co-authors of E. Grigoryeva

This figure shows the co-authorship network connecting the top 25 collaborators of E. Grigoryeva. A scholar is included among the top collaborators of E. Grigoryeva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Grigoryeva. E. Grigoryeva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Lebbé, Célèste, Nicolás Meyer, Laurent Mortier, et al.. (2019). Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. Journal of Clinical Oncology. 37(11). 867–875. 248 indexed citations

2.

Long, Georgina V., Scott S. Tykodi, Jeffrey Schneider, et al.. (2018). Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Annals of Oncology. 29(11). 2208–2213. 122 indexed citations

3.

Lebbé, Célèste, Nicolás Meyer, Laurent Mortier, et al.. (2018). Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511). Annals of Oncology. 29. viii737–viii737. 3 indexed citations

4.

Куницына, М. А., et al.. (2018). COMORBIDITY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. Vrach. 29(1). 1 indexed citations

5.

Schadendorf, Dirk, Paolo A. Ascierto, John B.A.G. Haanen, et al.. (2017). Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).. Journal of Clinical Oncology. 35(15_suppl). 9524–9524. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact